Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-05-05T18:05:07Z No. of bitstreams: 1 fabrizziocondedeoliveira.pdf: 6115188 bytes, checksum: 9810536208119e2012e4ee9015470c3e (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-06-07T15:41:26Z (GMT) No. of bitstreams: 1 fabrizziocondedeoliveira.pdf: 6115188 bytes, checksum: 9810536208119e2012e4ee9015470c3e (MD5) / Made available in DSpace on 2016-06-07T15:41:26Z (GMT). No. of bitstreams: 1 fabrizziocondedeoliveira.pdf: 6115188 bytes, checksum: 9810536208119e2012e4ee9015470c3e (MD5) Previous issue date: 2015-11-26 / CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Estudos de associação em escala genômica buscam encontrar marcadores moleculares do tipo SNP que estão associados direta ou indiretamente a um fenótipo em questão tais como, uma ou mais características do indivíduo ou, até mesmo, uma doença. O SNP pode ser a própria mutação causal ou pode estar correlacionado com a mesma por serem herdados juntos. Para identi car a região causadora ou promotora do fenótipo, a qual não é conhecida a priori, milhares ou milhões de SNPs são genotipados em amostras compostas de centenas ou milhares de indivíduos. Com isso, surge o desa o de selecionar os SNPs mais informativos no conjunto de dados genotípico, onde o número de atributos é, geralmente, muito superior ao número de indivíduos, com a possibilidade de que existam atributos altamente correlacionados e, ainda, podendo haver interações entre pares, trios ou combinações de SNPs de quaisquer ordens. Os métodos mais usados em estudos de associação em escala genômica utilizam o valor-p de cada SNP em testes estatísticos de hipóteses, baseados em regressão para fenótipos contínuos e baseados nos testes qui-quadrado ou similares em classi cação para fenótipos discretos, como ltro para selecionar os SNPs mais signi cativos. Entretanto, essa classe de métodos captura somente SNPs com efeitos aditivos, pois a relação adotada é linear. Na tentativa de superar as limitações de procedimentos já estabelecidos, este trabalho propõe um novo método de seleção de SNPs baseado em técnicas de Aprendizado de Máquina e Inteligência Computacional denominado SNP Markers Selector (SMS). O modelo é construído a partir de uma abordagem que divide o problema de seleção de SNPs em três fases distintas: a primeira relacionada à análise de relevância dos marcadores, a segunda responsável pela de nição do conjunto de marcadores relevantes que serão considerados por meio de uma estratégia de corte com base em um limite de relevância dos marcadores e, nalmente, uma fase para o re namento do processo de corte, geralmente para diminuir marcadores falsos-positivos. No SMS, essas três etapas, foram implementadas utilizando-se Florestas Aleatórias, Máquina de Vetores Suporte e Algoritmos Genéticos respectivamente. O SMS objetiva a criação de um uxo de trabalho que maximize o potencial de seleção do modelo através de etapas complementares. Assim, espera-se aumentar o potencial do SMS capturar efeitos aditivos e/ou não-aditivos com interação moderada entre pares e trios de SNPs, ou até mesmo, interações de ordens superiores com efeitos que sejam minimamente detectáveis. O SMS pode ser aplicado tanto em problemas de regressão (fenótipo contínuo) quanto de classi cação (fenótipo discreto). Experimentos numéricos foram realizados para avaliação do potencial da estratégia apresentada, com o método sendo aplicado em sete conjuntos de dados simulados e em uma base de dados real, onde a capacidade de produção de leite predita de vacas leiteiras foi medida como fenótipo contínuo. Além disso, o método proposto foi comparado com os métodos baseados no valor-p e com o Lasso Bayesiano apresentando, de forma geral, melhores resultados do ponto de vista de SNPs verdadeiros-positivos nos dados simulados com efeitos aditivos juntamente com interações entre pares e trios de SNPs. No conjunto de dados reais, baseado em 56.947 SNPs e um único fenótipo relativo à produção de leite, o método identi cou 245 QTLs associados à produção e à composição do leite e 90 genes candidatos associados à mastite, à produção e à composição do leite, sendo esses QTLs e genes identi cados por estudos anteriores utilizando outros métodos de seleção. Assim, o método demonstrou ser competitivo frente aos métodos utilizados para comparação em cenários complexos, com dados simulados ou reais, o que indica seu potencial para estudos de associação em escala genômica em humanos, animais e vegetais. / Genome-wide association studies have as main objective to discovery SNP type molecular markers associated directly or indirectly to a speci c phenotype related to one or more characteristics of an individual or even a disease. The SNP could be the causative mutation itself or correlated with the causative mutation due to common inheritance. Aiming to identify the causal or promoter region of the phenotype, which is unknown a priori, thousands or millions of SNPs are genotyped in samples composed of hundreds or thousands of individuals. Therefore, emerges the necessity to confront a challenge of selecting the most informative SNPs in genotype data set where the number of attributes are, usually, much higher than the number of individuals. Besides, the possibility of highly correlated attributes should be considered, as well as interactions between pairs, trios or combinations of high order SNPs. The most usual methods applied on genomewide association studies adopt the p-value of each SNP as a lter to select the SNPs most signi cant. For continuous phenotypes the statistical regression-based hypothesis test is used and the Chi-Square test or similar for classi cation of discrete phenotypes. However, this class of methods capture only SNPs with additive e ects, due to the linear relationship considered. In an attempt to overcome the limitations of established procedures, this work proposes a new SNPs selection method, named SNP Markers Selector (SMS), based on Machine Learning and Computational Intelligence strategies. The model is built considering an approach which divides the SNPs selection problem in three distinct phases: the rst related to the evaluation of the markers relevance, a second responsible for the de nition of the set of the relevant markers that will be considered by means of a cut strategy based on a threshold of markers relevance and, nally, a phase for the re nement of the cut process, usually to diminish false-positive markers. In the SMS, these three steps were implemented using Random Forests, Support Vector Machine and Genetic Algorithms, respectively. The SMS intends to create a work ow that maximizes the SNPs selection potential of the model due to the adoption of steps considered complementary. In this way, there is an increasing expectation on the performance of the SMS to capture additive e ects, moderate non-additive interaction between pairs and trios of SNPs, or even, higher order interactions with minimally detectable e ects. The SMS can be applied both in regression problems (continuous phenotype) as in classi cation problems (discrete phenotype). Numerical experiments were performed to evaluate the potential of the strategy, with the method being applied in seven sets of simulated data and in a real data set, where milk production capacity predicated of dairy cows was measured as continuous phenotype. Besides, the comparison of the proposed method with methods based on p-value and Lasso Bayesian technique indicate, in general, competitive results from the point of view of true-positive SNPs using simulated data set with additive e ects in conjunction with interactions of pairs and trios of SNPs. In the real data, based on 56,947 SNPs and a single phenotype of milk production, the method identi ed 245 QTLs associated with milk production and composition and 90 candidate genes associated with mastitis, milk production and composition, standing out that these QTLs and genes were identi ed by previous studies using other selection methods. Thus, the experiments showed the potential of the method in relation to other strategies when complex scenarios with simulated or real data are adopted, indicating that the work ow developed to guide the construction of the method should be considered for genome-wide asociation studies in humans, animals and plants.

Abstract The metabolic syndrome is a cluster of components predisposing to type 2 diabetes and cardiovascular disease. Abdominal obesity and insulin resistance seem to be central in the metabolic syndrome, although no unifying pathophysiological mechanism is available. The aim of this thesis was to determine out how the variation in PTP1B and adiponectin gene as well as variations in the plasma adiponectin concentration contribute to the risk of obesity related diseases. PTP1B is a negative regulator of insulin signalling and therefore considered a candidate gene for type 2 diabetes. In the first study, it was found that three PTP1B polymorphisms studied have not strong impact on type 2 diabetes. However, one SNP may be slightly protective against type 2 diabetes, since it was more frequent in the healthy group compared to group of patients with type 2 diabetes. Another SNP was associated with body mass index (BMI). The combination of certain alleles of PTP1B and LEPR (leptin receptor) genes was also associated to BMI. Adiponectin is an adipocytokine expressed in adipose tissue. It has insulin sensitizing effects in liver and muscle and it has also beneficial effects on cardiovascular health. In the second study, the contribution of adiponectin genotypes with obesity-related phenotypes was studied. In Caucasians, the carriers of rare allele of Tyr111His polymorphism were more insulin resistant and at a higher risk of developing type 2 diabetes. In African-Americans, other polymorphisms were associated with BMI and lipids. Thus, the effects of polymorphisms on obesity related phenotypes seemed to be different between ethnic groups. Plasma adiponectin levels were measured from different study groups. In the third study, it was found out that low plasma adiponectin levels associated with different components of the metabolic syndrome and there was a trend towards reductions in adiponectin with an increasing number of components. Fourth study indicated that baseline low adiponectin level associated with a more than 2-fold risk for developing impaired glucose tolerance or type 2 diabetes in the follow-up study of normoglycemic middle-aged Finnish subjects. In the fifth study, plasma adiponectin levels were measured from postmenopausal women receiving estrogen replacement therapy. We observed a reduction in adiponectin levels in women having peroral estradiol which could be part of the "early harm" profile on cardiovascular risk factors of the peroral estrogen replacement therapy detected in clinical trials. These studies further strengthen the role of plasma adiponectin in the obesity related diseases and bring new information of polymorphisms in the adiponectin and PTP1B genes in different populations. / Tiivistelmä Metabolinen oireyhtymä on kertymä tekijöitä, jotka altistavat tyypin 2 diabetekselle ja sydän- ja verisuonitaudeille. Keskivartalolihavuus ja insuliiniresistenssi, eli insuliinin heikentynyt teho, vaikuttavat olevan keskeisiä metabolisessa oireyhtymässä. Kuitenkaan taustalla olevaa syntymekanismia ei täysin tunneta. Väitöskirjatyön tavoitteena oli tutkia PTP1B- ja adiponektiinigeenin muuntelun sekä plasman adiponektiinitason yhteyttä metaboliseen oireyhtymään, sen osatekijöihin ja seurauksiin. PTP1B on insuliinin toimintaa soluissa estävä molekyyli. Ensimmäisessä tutkimuksessa havaittiin että kolme tutkittua PTP1B-geenin nukleotidimuutosta eivät ole vahvasti yhteydessä tyypin 2 diabetekseen. Eräs nukleotidimuutos saattaisi olla lievästi suojaava tyypin 2 diabetesta vastaan, sillä se oli yleisempi terveillä kuin tyypin 2 diabetesta sairastavilla. PTP1B:n ja leptiinireseptorigeenin eräiden alleelien yhdistelmä oli yhteydessä painoindeksiin. Adiponektiini on rasvakudoksen erittämä hormoni, jolla on suotuisia, insuliinin vaikutusta edesauttavia vaikutuksia elimistössä sekä edullisia vaikutuksia verenkiertoelimistössä. Toisessa työssä havaittiin että Amerikan valkoihoisilla, joilla oli eräs harvinainen adiponektiinigeenin alleeli (Tyr111His), oli heikompi insuliinin teho kuin henkilöillä joilla ei ollut kyseistä muutosta. Tämä alleeli oli yleisempi suomalaisilla tyypin 2 diabetesta sairastavilla kuin terveillä, mikä saattaa tarkoittaa että se liittyy suurentuneeseen riskiin tyypin 2 diabetekselle. Afroamerikkalaisilla taas toiset nukleotidimuutokset olivat yhteydessä lihavuuteen ja plasman rasva-arvoihin. Adiponektiinin pitoisuutta plasmassa mitattiin erilaisissa aineistoissa. Kolmannessa tutkimuksessa havaittiin, että matala pitoisuus oli yhteydessä metabolisen oireyhtymän eri osatekijöihin ja pitoisuus oli sitä matalampi, mitä enemmän osatekijöitä henkilöllä on. Neljännessä tutkimuksessa havaittiin että matala plasman adiponektiinipitoisuus oli yhteydessä suurentuneeseen riskiin saada huonontunut glukoosin sietokyky tai tyypin 2 diabetes tulevaisuudessa. Viidennessä tutkimuksessa adiponektiinitaso määritettiin naisilta jotka olivat ohittaneet vaihdevuodet ja saivat estrogeenikorvaushoitoa. Havaittiin että plasman adiponektiinitaso laski niillä naisilla, jotka saivat korvaushoitoa suun kautta. Tämä saattaisi osittain selittää suun kautta annettavan estrogeenikorvaushoidon epäedullista vaikutusta sydän ja -verisuonitautien riskitekijöihin. Tutkimus vahvistaa edelleen adiponektiinin merkitystä lihavuuteen liittyvissä sairauksissa ja tuo uutta tietoa adiponektiini- ja PTP1B-geenien muuntelun merkityksestä eri väestöissä.

Les études d’association pan-génomiques ont révélé plusieurs variants génétiques associés à des traits complexes. Les mesures érythrocytaires ont souvent fait l’objet de ce genre d’études, étant mesurées de façon routinière et précise. Comprendre comment les variations génétiques influencent ces phénotypes est primordial étant donné leur importance comme marqueurs cliniques et leur influence sur la sévérité de plusieurs maladies. En particulier, des niveaux élevés d’hémoglobine fœtal chez les patients atteints d’anémie falciforme est associé à une réduction des complications et une augmentation de l’espérance de vie. Néanmoins, la majorité des variants génétiques identifiés par ces études tombent à l’intérieur de régions génétiques non-codantes, augmentant la difficulté d’identifier des gènes causaux. L’objectif premier de ce projet est l’identification et la caractérisation de gènes influençant les traits complexes, et tout particulièrement les traits sanguins. Pour y arriver, j’ai tout d’abord développé une méthode permettant d’identifier et de tester l’effet de gènes knockouts sur les traits anthropométriques. Malgré un échantillon de grande taille, cette approche n’a révélé aucune association. Ensuite, j’ai caractérisé le méthylome et le transcriptome d’érythroblastes différentiés à partir de cellules souches hématopoïétiques et identifié plusieurs gènes potentiellement impliqués dans les programmes érythroïdes fœtaux et adultes. Par ailleurs, j’ai identifié plusieurs micro-ARNs montrant des motifs d’expression spécifiques entre les stages fœtaux et adultes et qui sont enrichis pour des cibles exprimées de façon opposée. Finalement, j’ai identifié plusieurs variants génétiques associés à l’expression de gènes dans les érythroblastes (eQTL). Cette étude a permis d’identifier des variants associés à l’expression du gène ATP2B4, qui encode le principal transporteur de calcium des érythrocytes. Ces variants, qui sont également associés à des traits sanguins et à la susceptibilité à la malaria, tombent dans un élément d’ADN spécifique aux cellules érythroïdes. La délétion de cet élément par le système CRISPR/Cas9 induit une forte diminution de l’expression du gène et une augmentation des niveaux de calcium intracellulaires. En conclusion, des échantillons de génotypages exhaustifs seront nécessaires pour étudier l’effet de gènes knockouts sur les traits complexes. Les érythroblastes montrent de grandes différences au niveau de leur méthylome et transcriptome entre les différents stages développementaux. Ces différences influencent potentiellement la régulation de l’hémoglobine fœtale et impliquent de nombreux micro-ARNs et régions régulatrices non-codantes. Finalement, l’exemple d’ATP2B4 montre qu’intégrer des études épigénomiques, transcriptomiques et des expériences d’édition de génome est une approche puissante pour caractériser des variants génétiques non-codants. Par ailleurs, ces résultats impliquent ATP2B4 dans l’hydratation des érythroblastes, qui est associé à la susceptibilité à la malaria et la sévérité de l’anémie falciforme. Cibler ATP2B4 de façon thérapeutique pourrait avoir un impact majeur sur ces maladies qui affectent des millions d’individus à travers le monde. / Genome-wide association studies (GWAS) have revealed several genetic variants associated with complex phenotypes. This is the case for red blood cell (RBC) traits, which are particularly amenable to GWAS as they are routinely and accurately measured. Understanding RBC trait variation is important given their significance as clinical markers and modifiers of disease severity. Notably, increased fetal hemoglobin (HbF) production in sickle cell disease (SCD) patients is associated with a higher life expectancy and decreased morbidity. Nonetheless, most variants identified through GWAS fall in non-coding regions of the human genome, increasing the difficulty of identifying causal links. The main goal of this project was to identify and characterize genes influencing complex traits, and in particular RBC phenotypes. First, I developed an approach to identify and test potential gene knockouts affecting anthropometric traits in a large sample from the general population, which did not yield significant associations. Then, I characterized the DNA methylome and transcriptome of erythroblasts differentiated ex vivo from hematopoietic progenitor stem cells (HPSC), and identified several genes potentially implicated in fetal and adult-stage erythroid programs. I also identified microRNAs (miRNA) that show specific developmental expression patterns and that are enriched in inversely expressed targets. Finally, I mapped expression quantitative trait loci (eQTL) in erythroblasts, and identify erythroid-specific eQTLs for ATP2B4, the main calcium ATPase of RBCs. These genetic variants are associated with RBC traits and malaria susceptibly, and overlap an erythroid-specific enhancer of ATP2B4. Deletion of this regulatory element using CRISPR/Cas9 experiments in human erythroid cells minimized ATP2B4 expression and increased intracellular calcium levels. In conclusion, large and comprehensive genotyping datasets will be necessary to test the role of rare gene knockouts on complex phenotypes. The transcriptomes and DNA methylomes of erythroblasts show substantial differences correlating with their developmental stages and that may be implicated in HbF production. These results also suggest a strong implication of erythroid enhancers and miRNAs in developmental stage specificity. Finally, characterizing the erythroid-specific enhancer of ATP2B4 suggest that integrating epigenomic, transcriptomic and gene editing experiments can be a powerful approach to characterize non-coding genetic variants. These results implicate ATP2B4 in erythroid cell hydration, which is associated with malaria susceptibility and SCD severity, suggesting that therapies targeting this gene could impact diseases affecting millions of individuals worldwide.

Abstract Each year in Finland, approximately 5.7% of infants are born preterm, i.e., before 37 completed weeks of gestation. Preterm birth is a major cause of mortality and several neonatal morbidities, especially the respiratory diseases. Infants born very preterm (<32 wk) are at higher risk of developing a chronic lung disease called bronchopulmonary dysplasia (BPD). The genetic factors predisposing to spontaneous preterm birth (SPTB) and BPD are incompletely known. The aims of this thesis project were to identify genetic factors that affect susceptibility to SPTB and BPD. Genetic case-control association studies were performed in mothers and infants of northern Finnish origin (SPTB study), or in multiple populations of very preterm infants of Finnish or European origin (BPD study). The candidate genes were selected based on their proposed roles in inflammation which is involved in both SPTB and BPD susceptibility. Additionally, the aim was to study the possible functional role of polymorphisms in the gene encoding surfactant protein B (SP-B) that have been shown previously to associate with pulmonary function. An association between Met31Thr polymorphisms in the gene encoding SP-D (SFTPD) and SPTB infants was found. The other collectin genes that were studied, encoding SP-A and mannose-binding lectin, did not associate with SPTB in mothers or infants. An intronic polymorphism in the gene encoding Kit ligand (KITLG) was associated with the risk of BPD in the northern Finnish and in the combined population that originated from Finland, Canada and Hungary. The role of KITLG in BPD was further supported by biomarker data, which showed higher concentrations of Kit ligand at the time of birth in infants that later developed BPD. The genes encoding interleukin 6 (IL-6), its receptors, IL-10, tumor necrosis factor alpha or glucocorticoid receptor did not associate with BPD susceptibility. Finally, a genetic variant 131Thr in the gene encoding SP-B (SFTPB) was associated with lower SP-B levels in vivo and delayed secretion in vitro. To date, there is no effective method to prevent SPTB, and especially the extremely preterm infants are at an increased risk of developing serious respiratory diseases. Better understanding of the mechanisms underlying both SPTB and BPD could help in the successful prediction of risk groups as well as in the design of new preventive and treatment strategies. / Tiivistelmä Noin 5,7 % lapsista syntyy Suomessa ennenaikaisesti, eli ennen kuin raskaus on kestänyt täydet 37 viikkoa. Ennenaikainen syntymä altistaa vastasyntyneen lapsen vakaville pitkäaikaissairauksille. Erityisesti hyvin pienillä keskosilla, jotka ovat syntyneet ennen 32. raskausviikkoa, on suurempi riski sairastua vakavaan hengitysvaikeuteen eli bronkopulmonaaliseen dysplasiaan, joka tunnetaan myös nimellä BPD-tauti. Perinnölliset tekijät vaikuttavat niin spontaanin ennenaikaisen syntymän (SEAS) kuin BPD-taudinkin taustalla, mutta nämä tekijät tunnetaan huonosti. Tässä väitöskirjatyössä pyrittiin tunnistamaan perinnöllisiä tekijöitä, jotka vaikuttavat SEAS:in ja BPD-taudin taustalla. Perinnöllisen taustan selvittämisessä ehdokasgeenien sisältämien muuntelevien kohtien esiintyvyyttä verrattiin terveiden verrokkien ja tautitapausten välillä. SEAS-tutkimuksessa tutkimusväestö koostui suomalaisista äideistä ja heidän lapsistaan. BPD-tutkimuksessa oli mukana hyvin ennenaikaisesti syntyneitä lapsia Suomesta, Kanadasta ja Unkarista. Tämän lisäksi kokeellisten tutkimusten avulla tutkittiin aiemmin keuhkosairauksiin liittyneen geenin muuntelevien kohtien osuutta sen koodaaman surfaktanttiproteiini (SP) B:n toiminnassa. Tutkimuksissa havaittiin SP-D:tä koodaavan geenin Met31Thr-polymorfismin olevan mahdollinen riskitekijä SEAS:lle lapsilla, mutta se ei selittänyt SEAS-riskiä äideissä. SP-A:ta ja mannoosia sitovaa lektiiniä koodaavilla geeneillä ei ollut yhteyttä SEAS-riskiin. Kit-ligandia koodaavan geenin intronissa sijaitseva polymorfismi selitti BPD-tautiriskiä pohjoissuomalaisessa sekä yhdistetyssä tutkimusväestössä. Lisäksi lapsilla, jotka myöhemmin sairastuivat BPD-tautiin, havaittiin suurempia Kit-ligandipitoisuuksia syntymähetkellä. Interleukiini 6:ta (IL-6), sen reseptoreita, IL-10:ta, tuumorinekroosifaktori-alfaa tai glukokortikoidireseptoria koodaavien geenien polymorfismien ja BPD-taudin välillä ei ollut yhteyttä. SP-B:tä koodaavan geenin Ile131Thr-polymorfismin Thr-variaatio liittyi alhaisempaan SP-B:n pitoisuuteen lapsivedessä sekä hidastuneeseen proteiinin tuottoon kokeellisessa solumallissa. Tulokset antavat uutta tietoa SEAS:n ja BPD-taudin perinnöllisestä taustasta. Tämä tieto voi auttaa synnytyksen käynnistymiseen sekä BPD-alttiuteen johtavien biologisten mekanismien selvittämisessä ja uusien hoitokeinojen kehittämisessä.

The TRIB1 locus (8q24.13) is a novel locus associated with plasma TGs and CAD risk. Trib1 is a regulator of MAPK activity, and has been shown to regulate hepatic lipogenesis and VLDL production in mice. However, the functional relationship between common SNPs at the TRIB1 locus and plasma lipid traits is unknown; TRIB1 has not been identified as an eQTL. This cluster of SNPs falls within an intergenic region 25kb to 50kb downstream of the TRIB1 coding region. By phylogenetic footprinting analysis and DNA genotyping, we identified an evolutionarily conserved region (CNS1) within the risk locus that harbours two common SNPs in tight LD with GWAS risk SNPs and significantly associated with CAD. We investigated the regulatory function of CNS1 by luciferase reporter assays in HepG2 cells and demonstrate that this region has promoter activity. In addition, the rs2001844 risk allele significantly reduces luciferase activity, suggesting that altered expression of the EST-based gene may be associated with plasma TGs. We identified an EST within the risk locus directly downstream of CNS1. We performed 5'/3' RACE using HepG2 RNA, identified multiple variants of this EST-based gene, and confirmed its transcription start site within CNS1. We hypothesize that this EST is a long noncoding RNA due to low abundance, poor conservation, and absence of significant ORF. Over-expression of a short variant implicates its function in the regulation of target gene transcription, although the mechanism of action remains unknown. We conclude that the risk locus at 8q24.13 harbours a novel EST-based gene that may explain the relationship between GWAS SNPs at this locus and plasma lipid traits.

L’asthme est une maladie inflammatoire chronique des voies respiratoires. C’est une maladie complexe et hétérogène, présentant un large spectre de manifestations cliniques dans lequel l’âge de début joue un rôle important. L’asthme résulte de nombreux facteurs génétiques et environnementaux et des interactions entre ces facteurs.Afin d’identifier de nouveaux gènes de susceptibilité à l’asthme et aux maladies allergiques, nous avons réalisé des études d’association pan-génomiques et de clonage positionnel en prenant en compte des mécanismes complexes : 1) empreinte parentale, 2) hétérogénéité de la maladie et 3) interactions gène-environnement.Nous avons tout d’abord réalisé une étude de clonage positionnel pour le phénotype asthme-plus-rhinite dans des familles d’origine européenne de quatre études indépendantes (770 familles recensées par un asthmatique et incluant 3200 sujets) en prenant en compte l'effet de l'origine parentale. L’intégration de données génétiques et épigénétiques, nous a permis d’identifier un mécanisme de médiation de l’effet d’un variant génétique transmis par le père sur le phénotype combiné asthme-plus-rhinite, par une méthylation différentielle d’un site CpG localisé dans le gène MTNR1A.Nous avons ensuite pris en compte la variabilité de l’âge de début de l'asthme dans la modélisation de la maladie par des méthodes d’analyse de survie et avons réalisé une méta-analyse d’études d'association pan-génomiques du délai de survenue de l’asthme dans neuf populations d’origine européenne (5462 asthmatiques et 8424 non asthmatiques). Nous avons ainsi identifié un nouveau locus de susceptibilité à l’asthme localisé dans la région 16q12. Nous avons également mis en évidence que les variants génétiques des régions 9p24 et 17q12-q21 étaient associés à un asthme précoce alors que les variants en 16q12 étaient associés à un asthme plus tardif. Enfin, nous avons réalisé une méta-analyse de cinq études d’interaction pan-génomiques du délai de survenue de l’asthme avec l’exposition au tabagisme passif dans l’enfance (3643 exposés et 5275 non-exposés). Nous avons montré que l’effet des variants génétiques des régions 9p24 et 17q12-q21 sur le délai de survenue de l’asthme était augmenté par l’exposition au tabagisme parental dans l’enfance.La prise en compte de mécanismes complexes dans les études génétiques, nous a permis d’identifier de nouveaux gènes de susceptibilité à l’asthme et de mieux comprendre les mécanismes physiopathologiques à l'origine de l’asthme et de son expression variable au cours de la vie. / Asthma is a chronic airway inflammatory disease. It is a complex and heterogeneous disease with a wide spectrum of clinical manifestations in which the age of onset plays an important role. Asthma results from many genetic and environmental factors and from interactions between these factors.To identify new susceptibility genes to asthma and allergic diseases, we performed genome-wide association studies and positional cloning studies, while taking into account complex mechanisms: 1) parental imprinting, 2) heterogeneity of the disease and 3) gene-by-environment interactions.We first conducted a positional cloning study for asthma-plus-rhinitis in European families of four independent studies (770 families ascertained through an asthmatic and including 3200 subjects) while taking into account parent-of-origin effects. The integration of genetic and epigenetic data enabled us to identify that the effect of a paternally inherited genetic variant on the combined phenotype asthma-plus-rhinitis was mediated by a differentially methylated CpG site within MTNR1A gene. We then took into account the variability of age-of-asthma onset in the disease modeling using survival analysis methods and conducted a meta-analysis of genome-wide association studies of time-to-asthma onset in nine European populations (5,462 asthmatics and 8,424 non-asthmatics). We identified a new asthma susceptibility locus in 16q12. We also showed that genetic variants of 9p24 and 17q12-q21 regions were associated with early-onset asthma while 16q12 variants were associated with later-onset asthma. Finally, we performed a meta-analysis of five genome-wide interaction studies of time-to-asthma onset with early-life tobacco smoke exposure (3,643 exposed and 5,275 unexposed). We showed that the effect of genetic variants of 9p24 and 17q12-q21 regions on time-to-asthma onset was increased by early-life tobacco smoke exposure.Studying complex mechanisms in genetic studies led to identify new asthma susceptibility genes and to better understand the pathophysiological mechanisms underlying asthma and its variable expression throughout life.

Le mélanome cutané est un cancer des cellules de la peau (mélanocytes) qui se situe, en France, au 11e rang des cancers les plus fréquents. Sa mortalité reste élevée lorsqu’il est diagnostiqué à un stade tardif. Ce cancer résulte de nombreux facteurs génétiques, environnementaux et des interactions entre ces facteurs. La susceptibilité génétique à ce cancer recouvre un large spectre de variabilité génétique, depuis des mutations rares conférant un risque élevé jusqu’à des variants fréquents conférant un risque modeste. C’est dans le cadre de l’identification de variants fréquents liés à l’apparition du mélanome et à son pronostic que se situe mon travail de thèse. À ce jour, les études d’associations pangénomiques du mélanome ont identifié des variants fréquents à effets relativement modestes qui expliquent seulement une part de la composante génétique. Les variants fonctionnels au sein des régions identifiées sont le plus souvent inconnus. Les études pangénomiques ont eu principalement recours à des analyses simple-marqueur qui peuvent manquer de puissance pour détecter des variants ayant un effet individuel faible ou interagissant avec d’autres variants. L’objectif principal de ce travail de thèse a été de proposer des stratégies d’analyse multi-marqueurs pour identifier de nouveaux gènes impliqués dans le mélanome et pour caractériser des variants potentiellement fonctionnels au sein des régions du génome associées au mélanome.Pour identifier de nouveaux gènes associés au risque de mélanome et à un facteur pronostique de ce cancer (l’indice de Breslow), nous avons proposé une stratégie d’analyse multi-marqueurs qui intègre une analyse de pathways biologiques basée sur la méthode GSEA (Gene Set Enrichment Analysis) et une analyse d’interactions entre gènes au sein des pathways associés au mélanome. Ces analyses ont été menées dans deux études : l’étude française MELARISK et l’étude américaine du MD Anderson Cancer Center (MDACC), totalisant 2 980 cas et 3 823 témoins. Nous avons identifié une interaction entre les gènes, TERF1 et AFAP1L2, pour le risque de mélanome et une interaction entre les gènes, CDC42 et SCIN, pour l’indice de Breslow. Ces gènes sont particulièrement pertinents sur le plan biologique du fait de leur rôle dans la biologie des télomères pour la première paire de gènes et dans la dynamique des filaments d’actine pour la seconde paire. Afin d’identifier les variants potentiellement fonctionnels au sein des régions du génome mises en évidence par études pangénomiques, nous avons proposé une stratégie de cartographie fine qui repose principalement sur une méthode de régression pénalisée (méthode HyperLasso) appliquée à tous les variants de la région étudiée. Par l’analyse de la région 16q24 qui contient le gène MC1R dont les variants fonctionnels sont connus, nous avons montré que cette stratégie était capable d’identifier ces variants parmi de nombreux variants associés au mélanome dans cette région. Nous avons contribué à identifier cinq nouvelles régions du génome associées au mélanome par méta-analyse d’études pangénomiques réalisées au niveau mondial (43 000 sujets) puis mené une étude de cartographie fine de toutes les régions associées au mélanome, en se basant sur la stratégie proposée et validée dans la région 16q24. Les stratégies d’analyses multi-marqueurs proposées dans le cadre de ce travail de thèse ont permis d’identifier de nouveaux gènes associés au risque de mélanome et à un facteur pronostique de ce cancer et de caractériser les variants génétiques potentiellement fonctionnels au sein des régions du génome identifiées par études pangénomiques. / Cutaneous melanoma is a skin cancer developed from melanocytes. It is the 11th most common cancers in France. Mortality due to melanoma remains high when diagnosed at a late stage. This cancer results from many genetic, environmental factors and interactions between these factors. The genetic susceptibility to melanoma covers a broad spectrum of genetic variation, from rare mutations conferring high risk to common variants conferring low risk. My thesis was conducted in the framework of low-risk variants associated with melanoma occurrence and prognosis. To date, genome-wide association studies (GWAS) of melanoma have identified common variants with relatively modest effects which only explain a part of the genetic component of this cancer. Functional variants at the identified loci are mostly unknown. GWASs have been mainly conducted using single-marker analysis which may be underpowered to detect variants with small effect or interacting with each other. The main objective of this thesis was to propose multi-marker analysis strategies to identify novel genes involved in melanoma and to characterize potentially functional variants in chromosomal regions found associated with melanoma. To identify new genes associated with melanoma risk and a prognostic factor for this cancer (Breslow thickness), we proposed a multi-marker analysis strategy which integrates pathway analysis based on the GSEA (Gene Set Enrichment Analysis) method and gene-gene interaction analysis within melanoma-associated pathways. These analyses were conducted in two studies: the French MELARISK study and the North-American MD Anderson Cancer Center (MDACC) study, with a total of 2,980 cases and 3,823 controls. We identified gene-gene interactions between TERF1 and AFAP1L2 genes for melanoma risk and between CDC42 and SCIN genes for Breslow thickness. These genes are biologically relevant because of their role in telomere biology for the former gene pair and in actin dynamics for the latter pair. To identify potentially functional variants at loci identified by GWAS, we proposed a fine mapping strategy which is mainly based on a penalized regression approach (HyperLasso method) that can be applied to all variants of the region under study. By studying the 16q24 region which harbors the MC1R gene whose functional variants are known, we showed this strategy was able to identify those variants among many variants associated with melanoma in this region. We contributed to the identification of five novel regions associated with melanoma through a worldwide meta-analysis of melanoma GWASs (43,000 subjects) and conducted fine mapping of all melanoma-associated loci using the strategy we proposed and validated in the 16q24 region. The multi-marker strategies proposed in this work have allowed identifying new biologically relevant genes associated with risk of melanoma and a major melanoma prognostic factor and characterizing potentially functional genetic variants within regions identified by GWAS.

Introduction/Background: Guidelines from the World Health Organization currently recommend targeting a body mass index (BMI) between 18.5 and 24.9 kg/m2 based on the lowest risk of mortality observed in epidemiological studies. However, these recommendations are based on population observations and do not take into account potential inter-individual differences. We hypothesized that genetic and non-genetic differences in adiposity, anthropometric, and metabolic measures result in inter-individual variation in the optimal BMI. Methods: Genetic variants associated with BMI as well as related adiposity, anthropometric, and metabolic phenotypes (e.g. triglyceride (TG)) were combined into polygenic risk scores (PRS), cumulative risk scores derived from the weighted contributions of each variant. 387,692 participants in the UK Biobank were split by quantiles of PRS or clinical biomarkers such as C-reactive protein (CRP), and alanine aminotransferase (ALT). The BMI linked with the lowest risk of all-cause and cause-specific mortality outcomes (“nadir value”) was then compared across quantiles (“Cox meta-regression model”). Our results were replicated using the non-linear mendelian randomization (NLMR) model to assess causality. Results: The nadir value for the BMI–all-cause mortality relationship differed across percentiles of BMI PRS, suggesting inter-individual variation in optimal BMI based on genetics (p = 0.005). There was a difference of 1.90 kg/m2 in predicted optimal BMI between individuals in the top and bottom 5th BMI PRS percentile. Individuals having above and below median TG (p = 1.29×10-4), CRP (p = 7.92 × 10-5), and ALT (p = 2.70 × 10-8) levels differed in nadir for this relationship. There was no difference in the computed nadir between the Cox meta-regression or NLMR models (p = 0.102). Conclusions: The impact of BMI on mortality is heterogenous due to individual genetic and clinical biomarker level differences. Although we cannot confirm that are results are causal, genetics and clinical biomarkers have potential use for making more tailored BMI recommendations for patients. / Thesis / Master of Science (MSc) / The World Health Organization (WHO) recommends targeting a body mass index (BMI) between 18.5 - 24.9 kg/m2 for optimal health. However, this recommendation does not take into account individual differences in genetics or biology. Our project aimed to determine whether the optimal BMI, or the BMI associated with the lowest risk of mortality, varies due to genetic or biological variation. Analyses were conducted across 387,692 individuals. We divided participants into groups according to genetic risk for obesity or clinical biomarker profile. Our results show that the optimal BMI varies according to genetic or biomarker profile. WHO recommendations do not account for this variation, as the optimal BMI can fall under the normal 18.5 - 24.9 kg/m2 or overweight 25.0 – 29.0 kg/m2 WHO BMI categories depending on individual genetic or biomarker profile. Thus, there is potential for using genetic and/or biomarker profiles to make more precise BMI recommendations for patients.

No description available.

No description available.